CCM
ADPT icon

Catalio Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Catalio Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-722,784
Closed -$10M – 41
2026
Q1 		$10M Sell
722,784
-98,411
-12% -$1.57M 2.1% 20
2025
Q4 		$13.3M Sell
821,195
-63,695
-7% -$1.04M 2.36% 17
2025
Q3 		$13.2M Sell
884,890
-511,555
-37% -$6.23M 2.45% 20
2025
Q2 		$16.3M Buy
1,396,445
+784,806
+128% +$7.13M 3.41% 14
2025
Q1 		$4.54M Buy
+611,639
New +$4.7M 1.11% 21

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Catalio Capital Management's ADPT Position: Q2 2026 in Review

Catalio Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 722,784 shares — an estimated $10M sold.

Catalio Capital Management first reported a position in ADPT in Q1 2025 and held it in 5 quarters. The position peaked at $16.3M in Q2 2025. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Catalio Capital Management reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Catalio Capital Management sold 722,784 Adaptive Biotechnologies shares in Q2 2026, an estimated $10M.
  • Catalio Capital Management first reported a position in Adaptive Biotechnologies in Q1 2025 and held it in 5 quarters.
  • Catalio Capital Management's Adaptive Biotechnologies position peaked at $16.3M in Q2 2025.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.